Human sympathetic ganglion organoids support investigation of sympathetic innervation of target organs
08 January 2026 While the human central nervous system (CNS) has often been modelled with organoids, progress in constructing the peripheral nervous system (PNS) has been relatively limited. Yet, the PNS plays a crucial role in communication between different areas of the body and the brain and dysfunction in PNS has been tied to a number of chronic diseases. The PNS has two main subsystems, one of which is the autonomic nervous system, which automatically controls physio
Autologous human tumor-immune organoid model for patient-specific prediction of response to immunotherapy
27 January 2026 Despite important investment in biomedical research, the most common malignant adult brain tumor - glioblastoma (GBM) - remains largely refractory to existing treatments. Tumors can evade or suppress immunity through a variety of mechanisms, including antigen heterogeneity and immunosuppressive signaling. Owing in large part to inter-species differences in the immune system and the tumor microenvironment (extracellular matrix composition, stromal cells beha
Hesperos establishes strategic sales partnership with AsedaSciences to augment compound safety prediction
17 December 2025 Hesperos announces the establishment of a strategic channel sales and marketing partnership with AsedaSciences, offering its pharmaceutical, cosmetic, nutraceutical and chemical industry clients a powerful combination of human-based, in silico and in vitro tools for development of safer compounds. Traditionally, compound safety has been assessed using animal testing, but these models raise ethical concerns, lack human physiological relevance, and offer l
Heartbeat.bio partners with Boehringer Ingelheim to develop a gene therapy for cardiomyopathy
23 September 2025 Vienna-based Heartbeat.bio , developer of breakthrough therapies for cardiac disorders through its proprietary human-based in vitro cardioid drug discovery platform, announces it has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. Genetic cardiac pathologies such as hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathy, are typically c








